Albany Medical College, Albany, NY
Ilija Aleksic , Winnie Wang , Tucker Conklin , Igor Sorokin , Hugh A.G. Fisher , Ronald P. Kaufman Jr., Badar Mian , Barry Kogan , Brian McNeil , Andrew Winer , Raavi Gupta , A. Gregory DiRienzo , Martin Tenniswood
Background: Bladder cancer patients are routinely monitored after treatment by cystoscopy due to a high rate of recurrence. In the absence of an accurate non-invasive screening test to monitor recurrence, bladder cancer will remain the most expensive malignancy to manage. We have developed a non-invasive test that interrogates small non-coding RNAs (sncRNAs) present in urinary exosomes. Analyzing the urine exosome data with a novel statistical classification algorithm provides a platform that unequivocally differentiates between patients with no evidence of disease and those with recurrence. Methods: Urine samples were collected from patients previously treated for bladder cancer (n = 82) who are currently under routine surveillance cystoscopy. Patients without bladder cancer or without evidence of recurrent disease served as the control cohort. A Sentinel sncRNA signature specific for bladder cancer was generated by interrogation of urine exosomal RNAs on Affymetrix 4.0 arrays that probes for > 6600 sncRNAs. A customized platform to interrogate the most informative (~120) Sentinel sncRNAs, was then used to screen urine exosomal RNA derived from patients at risk for recurrent disease. Data were then analyzed using a statistical classification algorithm that provides the miR-BCPx (bladder cancer progression score). This novel analytical approach requires no a priori knowledge of the sncRNA function to generate an unbiased classification into those with stable disease versus those with recurrent tumor. Results: Bladder cancer patients have significantly elevated levels of exosomal RNA relative to control cohort. In a small blinded testing male cohort, comparison of the miR-BCPx score generated to the disease status demonstrates that the miR-BCPx identifies patients with recurrent tumor with 100% sensitivity (59/59) and 96% specificity (22/23). Conclusions: Implementation of the miR-BCPx as a surveillance screen for bladder cancer patients provides an affordable, non-invasive alternative to cystoscopy for monitoring disease stability, and can readily be deployed in the clinic to reduce the number of screening cystoscopies needed.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Genitourinary Cancers Symposium
First Author: Hanzhong Li
2024 ASCO Annual Meeting
First Author: Jungmin Jo
2023 ASCO Genitourinary Cancers Symposium
First Author: Tyler F. Stewart
2023 ASCO Genitourinary Cancers Symposium
First Author: Kyle M. Rose